Press Releases

CARLSBAD, Calif. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, October 28, 2020. Management will hold a conference call to review the company's financial

Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season RP2 Panel at a Glance GenMark’s ePlex ®   Respiratory Pathogen Panel 2 ( RP2 Panel) has received Emergency Use Authorization from the FDA.

Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth CARLSBAD, Calif. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens helps health care professionals prepare for flu season RP2 Panel at a Glance GenMark’s ePlex® Respiratory Pathogen Panel 2 ( RP2 ) has achieved CE mark. RP2 provides results in less than two hours for more than

Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity CARLSBAD, Calif. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that it has notified

CARLSBAD, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020 . Second Quarter 2020 Highlights Total revenue of

CARLSBAD, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.

CARLSBAD, Calif. , July 21, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Tuesday, August 4, 2020. Management will hold a conference call to review the company's financial

Second Quarter 2020 Revenue Expected to Represent Approximately 118% Year-Over-Year Growth CARLSBAD, Calif. , July 07, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary

Updated test provides rapid results for SARS-CoV-2 and other important respiratory pathogens and a simplified workflow CARLSBAD, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems,